Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed long‑acting injectable for pulmonary hypertension
Lila Bio, spun out of David Baker’s UW lab, won a $3.65 million NIH SBIR grant to develop an AI-designed, long-acting injectable protein therapy aimed at modifying disease in pulmonary hypertension. The funding covers two phases—$605,981 for initial animal studies and $3,049,462 for further animal work and patient lung-tissue studies—and builds on Lila’s 2023 $10M seed raise and prior collaboration with Eli Lilly.
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed protein therapy for pulmonary hypertension
Lila Bio received a $3.65 million NIH SBIR grant to develop AI-designed, long-acting injectable protein therapies that aim to modify the underlying disease in pulmonary hypertension; initial work is in lab and animal testing with further studies planned using patient lung tissue.
Joe Heitzeberg hosts 100% AI PhD dinner in Seattle with Lightspeed AI’s David Pitman and leading AI researchers
Joe Heitzeberg hosted a Seattle dinner of AI PhD practitioners and researchers where attendees from Lightspeed AI, academia, startups, and industry discussed deep AI science, explainability, generative models, and applied research without covering basic ML concepts.
See all 76 news stories about David Baker.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
See all 5-
Institute for Protein Design Director · current
-
University of Washington Professor / Institute Leader (Institute for Protein Design) · current
-
UW Institute for Protein Design Co-founder and Lab Head, Nobel Laureate · current